Multimodality approaches have improved clinical outcome in HNSCC, including surgery, chemotherapy, radiotherapy and therapeutics targeted EGFR.23, 24 However, there are still 50% of patients uncured,4, 11 which suggested an urgent need to detect other predictable biomarkers in HNSCC. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.